0000000000262821
AUTHOR
S. Vassalli
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry
AbstractBackgroundCurrently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). The study aimed to assess the incidence of clinical events and death in this population.MethodsThis was a cohort study on PWH from the PRESTIGIO Registry with a documented 4DR virus. Burden of disease was defined as the occurrence of any new event including an AIDS-defining event (ADE) or non-AIDS-defining event (NADE) or death from any cause after 4DR evidence (baseline). Co…
Le anime del paesaggio. Spazi, arte, letteratura
Tre maestri della modernità aprono sguardi nuovi sul paesaggio per vivere nella società odierna gli spazi di cultura, natura, arte e letteratura. Flavio Caroli, come in una delle sue presenze a che tempo che fa, dimostra che il paesaggio nella pittura va "dalla retina verso l'anima" accompagnandoci in un itinerario attraverso i quadri più celebri che raffigurano "il volto e l'anima della natura". Philippe Daverio apre una finestra sul paesaggio della modernità e tra curiosità, approfondimenti e intuizioni ribadisce che "il destino della città rappresenta oggi una questione che non può più essere ignorata, la domanda architettonica, e specificamente urbanistica, deve tornare al centro della …
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data
OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…